வீரியம் புள்ளிவிவரங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from வீரியம் புள்ளிவிவரங்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In வீரியம் புள்ளிவிவரங்கள் Today - Breaking & Trending Today

MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab

frontMIND Study Evaluating Tafasitamab Combination as a
First-line Treatment for Diffuse Large B-Cell Lymphoma
PLANEGG/MUNICH, Germany and WILMINGTON, Del., USA - May 11, 2021 - MorphoSys AG (FSE:MOR; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal Phase 3
frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) compared to R-CHOP alone as first-line treatment for high-intermediate and high-risk patients with untreated diffuse large B-cell lymphoma (DLBCL). Tafasitamab is a humanized, monoclonal antibody designed to effectively target the B-cell specific antigen CD19 and to induce immune cell activation. ....

United States , Italy General , Peter Langmuir , Mike Akimov , Practice Research Clinical Haematology , Head Of Global Drug Development , Janssen Biotech Inc , Xencor Inc , Janssen Research Development , Morphosys Us Inc , Distribution Services , American Society Of Hematology , Decision Resources Group , World Health Organization Subtypes , Drug Administration , Group Vice , German Lymphoma Association , Exchange Commission , European Medicines Agency , Us Oncology Network , Incyte Announce First Patient Dosed , Evaluating Tafasitamab Combination , First Line Treatment , Diffuse Largeb Cell , Global Drug Development , Group Vice President ,

MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma

MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma
ACCESSWIRE
12 May 2021, 06:05 GMT+10
PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / May 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal Phase 3
frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) compared to R-CHOP alone as first-line treatment for high-intermediate and high-risk patients with untreated diffuse large B-cell lymphoma (DLBCL). Tafasitamab is a humanized, monoclonal antibody designed to effectively target the B-cell specific antigen CD19 and to induce immune cell activation. ....

United States , Italy General , Peter Langmuir , Mike Akimov , Practice Research Clinical Haematology , Head Of Global Drug Development , Janssen Biotech Inc , Xencor Inc , Janssen Research Development , Morphosys Us Inc , American Society Of Hematology , Decision Resources Group , World Health Organization Subtypes , Drug Administration , Group Vice , German Lymphoma Association , Exchange Commission , European Medicines Agency , Us Oncology Network , Global Drug Development , Group Vice President , Oncology Targeted Therapeutics , American Society , Diffuse Largeb Cell Lymphoma , Italian Lymphoma , Blinded Independent Review Committee ,

Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma

Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , Italy General , Julia Neugebauer , Peter Langmuir , Mike Akimov , Myles Clouston , Jeanette Bressi , Thomas Biegi , Catalina Loveman , Christine Chiou , Jenifer Antonacci , Practice Research Clinical Haematology , Us Communications , Head Of Global Drug Development , Janssen Biotech Inc , Xencor Inc , Janssen Research Development , Morphosys Us Inc , American Society Of Hematology , Public Affairs , Decision Resources Group , World Health Organization Subtypes , Drug Administration , Group Vice , German Lymphoma Association , Exchange Commission ,

MorphoSys AG: MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma

MorphoSys AG: MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma
The
frontMIND (NCT04824092) trial is a randomized, double-blind, placebo-controlled, global Phase 3 clinical study in previously untreated high-intermediate and high-risk DLBCL patients that is conducted in partnership with the German Lymphoma Association (GLA), the Italian Lymphoma study group and the US Oncology Network.
The study aims to enroll approximately 880 DLBCL patients to receive either tafasitamab plus lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or R-CHOP alone. The primary endpoint is investigator-assessed progression-free survival, according to Lugano 2014 criteria, and key secondary endpoints include event-free survival by investigator, overall survival, metabolic complete response rate by a Blinded Independen ....

United States , Italy General , Julia Neugebauer , Peter Langmuir , Mike Akimov , Myles Clouston , Jeanette Bressi , Thomas Biegi , Catalina Loveman , Christine Chiou , Jenifer Antonacci , Practice Research Clinical Haematology , Us Communications , Head Of Global Drug Development , Janssen Biotech Inc , Xencor Inc , Janssen Research Development , Morphosys Us Inc , American Society Of Hematology , Public Affairs , Decision Resources Group , World Health Organization Subtypes , Drug Administration , Group Vice , German Lymphoma Association , Exchange Commission ,